Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, quantification

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87542 refers to a laboratory test designed for the detection of the infectious agent Legionella pneumophila through the analysis of nucleic acids, specifically DNA or RNA. Legionella pneumophila is a gram-negative bacterium commonly found in aquatic environments, which can lead to serious health issues such as pneumonia, known as Legionnaire’s Disease, or a milder illness resembling influenza, referred to as Pontiac Fever. This test utilizes a direct probe method to identify a unique nucleic acid sequence, termed the target sequence, associated with the L. pneumophila organism, should it be present in a respiratory specimen. The detection process involves the use of a probe that is labeled with either fluorescent or chemiluminescent markers. To perform the test, the sample is treated to release nucleic acids from the target organism, if it exists. The labeled probe then selectively binds to the matching target sequence, forming a stable hybrid. Ribosomal RNA is often the focus of this detection method due to its abundance in microorganisms, as it typically exists in thousands of copies compared to the limited 1-2 copies found in genomic DNA. The sensitivity of the assay is significantly enhanced through an amplified probe technique, which involves exponentially multiplying the target sequence of L. pneumophila DNA or RNA into millions of copies. The polymerase chain reaction (PCR) or reverse transcriptase polymerase chain reaction (RT-PCR) is the most frequently employed amplification technique. Following amplification, the replicated sequences are identified using labeled DNA probes. The quantification aspect of this test, as indicated by the CPT® Code 87542, provides a measurement of the number of microorganisms present in the sample. Quantitative or real-time PCR is typically utilized to amplify the isolated nucleic acid segment and generate a report that documents the absolute or relative amounts of the known nucleic acid sequence at each stage of the testing process.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 87542 is indicated for the detection and quantification of the infectious agent Legionella pneumophila in respiratory specimens. This test is particularly relevant for patients presenting with symptoms consistent with pneumonia or influenza-like illnesses, where the presence of L. pneumophila may be suspected. The following conditions may warrant the use of this test:

  • Pneumonia - Patients exhibiting symptoms of pneumonia, which may include cough, fever, chills, and difficulty breathing, may require testing for L. pneumophila to confirm the diagnosis.
  • Legionnaire’s Disease - This severe form of pneumonia caused by L. pneumophila necessitates accurate detection for appropriate treatment and management.
  • Pontiac Fever - A less severe illness caused by the same bacterium, characterized by flu-like symptoms, may also be an indication for testing.

2. Procedure

The procedure for CPT® Code 87542 involves several critical steps to ensure accurate detection and quantification of Legionella pneumophila. The following procedural steps are outlined:

  • Sample Collection - A respiratory specimen is collected from the patient, which may include sputum, bronchoalveolar lavage fluid, or other respiratory secretions. Proper collection techniques are essential to avoid contamination and ensure the integrity of the sample.
  • Nucleic Acid Extraction - The collected sample undergoes treatment to release nucleic acids from any L. pneumophila organisms present. This step is crucial for isolating the target nucleic acids necessary for detection.
  • Probe Hybridization - A labeled probe, specific to the target sequence of L. pneumophila, is introduced to the sample. The probe binds selectively to the target nucleic acid, forming a stable hybrid if the organism is present.
  • Amplification of Target Sequence - The assay employs an amplification technique, such as polymerase chain reaction (PCR) or reverse transcriptase polymerase chain reaction (RT-PCR), to exponentially increase the quantity of the target nucleic acid. This step enhances the sensitivity of the test, allowing for the detection of even low levels of the organism.
  • Detection and Quantification - Following amplification, the replicated nucleic acid sequences are identified using labeled DNA probes. The quantification process provides an assessment of the number of L. pneumophila microorganisms present in the sample, often utilizing quantitative or real-time PCR methods to generate a report detailing the absolute or relative amounts of the target nucleic acid.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 87542, the laboratory will analyze the results and generate a report detailing the presence and quantity of Legionella pneumophila in the sample. Clinicians will review these results to inform diagnosis and treatment decisions. It is important for healthcare providers to consider the clinical context and symptoms of the patient when interpreting the results. Follow-up care may include additional testing or treatment based on the findings, and patients may be monitored for any progression of symptoms or complications related to the detected infection.

Short Descr LEGION PNEUMO DNA QUANT
Medium Descr IADNA LEGIONELLA PNEUMOPHILA QUANTIFICATION
Long Descr Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, quantification
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GW Service not related to the hospice patient's terminal condition
XS Separate structure, a service that is distinct because it was performed on a separate organ/structure
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2011-01-01 Changed Short description changed.
1998-01-01 Added First appearance in code book in 1998.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"